Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Jan 09, 2025 4:00pm EST

Aptose Announces Positive Decision by Nasdaq Hearings Panel

Dec 19, 2024 4:05pm EST

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Dec 12, 2024 10:15am EST

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Dec 09, 2024 12:00pm EST

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Dec 03, 2024 7:30am EST

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Nov 25, 2024 4:15pm EST

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Nov 22, 2024 8:00am EST

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Nov 20, 2024 7:30am EST

Aptose Reports Results for the Third Quarter 2024

Nov 08, 2024 4:01pm EST

Aptose Announces Results from Special Meeting of Shareholders

Sep 05, 2024 4:15pm EDT